ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

ClinicalTrials.gov ID: NCT06874621

Public ClinicalTrials.gov record NCT06874621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease

Study identification

NCT ID
NCT06874621
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Voyager Therapeutics
Industry
Enrollment
52 participants

Conditions and interventions

Interventions

  • Placebo Comparator Drug
  • VY7523 Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 90 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2025
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027
Last update posted
Nov 18, 2025

2025 – 2027

United States locations

U.S. sites
19
U.S. states
7
U.S. cities
17
Facility City State ZIP Site status
VYGR Site 840018 Los Angeles California 90033
VYGR Site 840016 Orange California 92866
VYGR Site 840022 San Francisco California 94158
VYGR Site 840008 Stamford Connecticut 06905
VYGR Site 840005 Delray Beach Florida 33445
VYGR Site 840021 Fort Myers Florida 33912
VYGR Site 840010 Lady Lake Florida 32159
VYGR Site 840015 Miami Florida 33126
VYGR Site 840014 Miami Florida 33135
VYGR Site 840024 Miami Florida 33137
VYGR Site 840006 Orlando Florida 32803
VYGR Site 840003 Stuart Florida 34997
VYGR Site 840004 The Villages Florida 32162
VYGR Site 840002 Wellington Florida 33414
VYGR Site 840020 Winter Park Florida 32789
VYGR Site 840007 Decatur Georgia 30030
VYGR Site 840012 Toms River New Jersey 08755
VYGR Site 840009 Matthews North Carolina 28105
VYGR Site 840011 Plymouth Meeting Pennsylvania 19462

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06874621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2025 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06874621 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →